Dual gut hormone receptor agonists for diabetes and obesity

[1]  L. Aronne,et al.  Tirzepatide Once Weekly for the Treatment of Obesity. , 2022, The New England journal of medicine.

[2]  Minrong Ai,et al.  GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior , 2022, Diabetes.

[3]  T. Wadden,et al.  Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension , 2022, Diabetes, obesity & metabolism.

[4]  M. Tschöp,et al.  Anti-obesity drug discovery: advances and challenges , 2021, Nature reviews. Drug discovery.

[5]  Minrong Ai,et al.  Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation , 2021, Molecular metabolism.

[6]  Donal N. Gorman,et al.  Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial , 2021, Nature Medicine.

[7]  K. Gadde,et al.  Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study , 2021, Diabetes Care.

[8]  D. D’Alessio,et al.  GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells , 2021, Science Advances.

[9]  T. Wadden,et al.  Once-Weekly Semaglutide in Adults with Overweight or Obesity. , 2021, The New England journal of medicine.

[10]  M. Tschöp,et al.  Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists , 2021, Molecular metabolism.

[11]  M. Larsen,et al.  Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. , 2020, Nature metabolism.

[12]  F. Reimann,et al.  The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system , 2019, Peptides.

[13]  L. B. Knudsen,et al.  The Discovery and Development of Liraglutide and Semaglutide , 2019, Front. Endocrinol..

[14]  M. Tschöp,et al.  Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism , 2018, Molecular metabolism.

[15]  D. Bates,et al.  Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models , 2018, Science Translational Medicine.

[16]  M. Tschöp,et al.  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. , 2017, Cell metabolism.

[17]  M. Tschöp,et al.  The New Biology and Pharmacology of Glucagon. , 2017, Physiological reviews.

[18]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[19]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[20]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[21]  Kathryn C. Claiborn.  Masters of metabolism: Matthias Tschöp and Richard DiMarchi , 2011 .

[22]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[23]  J. Holst,et al.  Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. , 2005, Diabetes.

[24]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[25]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[26]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[27]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[28]  J. Brown,et al.  Further purification of a polypeptide demonstrating enterogastrone activity , 1970, The Journal of physiology.